| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Acticor Biotech SA
PAR:ALACT
Acticor Biotech SA
Research & Development
Acticor Biotech SA
Research & Development Peer Comparison
VLA
NANO
IPH
ABVX
Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
A
|
Acticor Biotech SA
PAR:ALACT
|
Research & Development
-€15m
|
CAGR 3-Years
-70%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Research & Development
-€89.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Nanobiotix SA
PAR:NANO
|
Research & Development
-€37.1m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-20%
|
|
|
Innate Pharma SA
PAR:IPH
|
Research & Development
-€49.4m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
G
|
Genfit SA
PAR:GNFT
|
Research & Development
-€35.9m
|
CAGR 3-Years
11%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Abivax SA
PAR:ABVX
|
Research & Development
-€103.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Acticor Biotech SA's Research & Development?
Research & Development
-15m
EUR
Based on the financial report for Jun 30, 2023, Acticor Biotech SA's Research & Development amounts to -15m EUR.
What is Acticor Biotech SA's Research & Development growth rate?
Research & Development CAGR 3Y
-70%
Over the last year, the Research & Development growth was -31%. The average annual Research & Development growth rates for Acticor Biotech SA have been -70% over the past three years .
You don't have any saved screeners yet
